{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T18:32:19Z","timestamp":1773081139251,"version":"3.50.1"},"reference-count":40,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1517\/14656566.8.4.477","type":"journal-article","created":{"date-parts":[[2007,2,19]],"date-time":"2007-02-19T12:27:42Z","timestamp":1171888062000},"page":"477-483","source":"Crossref","is-referenced-by-count":8,"title":["Abacavir sulfate\/lamivudine\/zidovudine fixed combination in the treatment of HIV infection"],"prefix":"10.1517","volume":"8","author":[{"given":"Philip","family":"Keiser","sequence":"first","affiliation":[{"name":"Professor of Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA"},{"name":"Medical Director, Department of HIV\/AIDS Services, Parkland Health and Hospital System, Dallas, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naiel","family":"Nassar","sequence":"additional","affiliation":[{"name":"Clinical Associate Professor of Medicine, University of California San Francisco \u2013 Fresno, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2007,2,19]]},"reference":[{"key":"e_1_3_1_2_1","first-page":"506","volume":"27","author":"DUBE","year":"2001","unstructured":"DUBE MP: Lipodystrophy and insulin resistance in patients with HIV. J. Acquir. Immune Defic. Syndr. (2001) 27(5):506-507.","journal-title":"J."},{"key":"e_1_3_1_3_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200124030-00001"},{"key":"e_1_3_1_4_1","first-page":"339","volume":"2","author":"BOUFASSA","year":"2001","unstructured":"BOUFASSA F, DULIOUST A, LASCAUX AS et al.: Lipodystrophy in 685 HIV-1-treated patients: influence of antiretroviral treatment and immunovirological response. HIV Clin. Trials (2001) 2(4):339-345.","journal-title":"HIV"},{"key":"e_1_3_1_5_1","unstructured":"GLAXOSMITHKLINE: Trizivir\u00ae (abacavir sulfate lamivudine and zidovudine) prescribing information. GlaxoSmithKline Research Triangle Park (NC) USA (2006)."},{"key":"e_1_3_1_6_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.19.11.932.31568"},{"key":"e_1_3_1_7_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.6.1686-1690.2000"},{"key":"e_1_3_1_8_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.8.2061-2067.2000"},{"key":"e_1_3_1_9_1","doi-asserted-by":"publisher","DOI":"10.1086\/322682"},{"key":"e_1_3_1_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/00912700122010096"},{"key":"e_1_3_1_11_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.21.5.424.34497"},{"key":"e_1_3_1_12_1","doi-asserted-by":"publisher","DOI":"10.1159\/000046045"},{"key":"e_1_3_1_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200110000-00010"},{"key":"e_1_3_1_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199901140-00007"},{"key":"e_1_3_1_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199816000-00001"},{"key":"e_1_3_1_16_1","doi-asserted-by":"publisher","DOI":"10.1086\/318527"},{"key":"e_1_3_1_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200108170-00009"},{"key":"e_1_3_1_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.9.1155"},{"key":"e_1_3_1_19_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079904125004006"},{"key":"e_1_3_1_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/135965350300800211"},{"key":"e_1_3_1_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.7.769"},{"key":"e_1_3_1_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031772"},{"key":"e_1_3_1_23_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-1293.2003.00139.x"},{"key":"e_1_3_1_24_1","first-page":"257","volume":"39","author":"MARKOWITZ","year":"2005","unstructured":"MARKOWITZ M, HILL-ZABALA C, LANG J et al.: Induction with abacavir\/lamivudine\/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir\/lamivudine\/ zidovudine alone in antiretroviral-naive HIV-1-infected patients. J. Acquir. Immune Defic. Syndr. (2005) 39(3):257-264.","journal-title":"J."},{"key":"e_1_3_1_25_1","first-page":"222","volume":"11","author":"SHAPIRO","year":"2001","unstructured":"SHAPIRO M, WARD KM, STERN JJ: A near-fatal hypersensitivity reaction to abacavir: case report and literature review. AIDS Read (2001) 11(4):222-226.","journal-title":"AIDS"},{"key":"e_1_3_1_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200101260-00027"},{"key":"e_1_3_1_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199907300-00026"},{"key":"e_1_3_1_28_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1A022"},{"key":"e_1_3_1_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08158-8"},{"key":"e_1_3_1_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)07873-X"},{"key":"e_1_3_1_31_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0307067101"},{"key":"e_1_3_1_32_1","doi-asserted-by":"publisher","DOI":"10.1086\/504874"},{"key":"e_1_3_1_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200211080-00017"},{"key":"e_1_3_1_34_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M106743200"},{"key":"e_1_3_1_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)90004-3"},{"key":"e_1_3_1_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199907300-00027"},{"key":"e_1_3_1_37_1","doi-asserted-by":"publisher","DOI":"10.1177\/135965350400900102"},{"key":"e_1_3_1_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki170"},{"key":"e_1_3_1_39_1","first-page":"422","volume":"40","author":"SOSA","year":"2005","unstructured":"SOSA N, HILL-ZABALA C, DEJESUS E et al.: Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL). J. Acquir. Immune Defic. Syndr. (2005) 40(4):422-427.","journal-title":"J."},{"key":"e_1_3_1_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200202150-00010"},{"key":"e_1_3_1_41_2_1","unstructured":"www.aids-info.org Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. May 4 2006."}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/14656566.8.4.477","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T22:04:44Z","timestamp":1770933884000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/14656566.8.4.477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2,19]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["10.1517\/14656566.8.4.477"],"URL":"https:\/\/doi.org\/10.1517\/14656566.8.4.477","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2,19]]}}}